

**Stefan Russmann, MD**

born 21 December 1970, Göttingen, Germany  
 Marital status: married, 2 children  
 Languages: German, English, French, Italian  
 Nationality: German  
 Swiss residence permit: C (permanent)

**Address:**

drugsafety.ch  
 Seestrasse 221  
 8700 Küsnacht ZH, Switzerland  
 phone: +41 44 221 1003  
 email: [russmann@drugsafety.ch](mailto:russmann@drugsafety.ch)

<b>Licensure</b>	2015 2008 2003 1999 1997	Licence to practice as an independent medical doctor in the Canton of Zurich Board-certified pharmacologist and toxicologist (German boards) FMH Clinical Pharmacology and Toxicology (Swiss boards) Board-certified clinical pharmacologist (German boards) United States Medical Licensing Examination (USMLE Steps I and II) MD degree, University of Freiburg, Faculty of Medicine, Germany
<b>Academic appointments</b>	2015 - present 2008  2009 - present 2005 - 2008	<b>University of Zurich, Faculty of Medicine, Zurich, Switzerland</b> Associate Professor (Titularprofessor) for Clinical Pharmacology and Toxicology Venia Legendi (Privatdozent) for Clinical Pharmacology and Toxicology  <b>Boston University School of Public Health, Boston, MA, USA</b> Adjunct Associate Professor of Epidemiology Assistant Professor of Epidemiology
<b>Doctoral thesis</b>	1998	<b>University of Freiburg, Faculty of Medicine (supervisor Prof. E. Jähnchen)</b> „Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery.“
<b>Professional positions</b>	2015 - present  2015 - present  2017 - present  2014 - present  2009 - 2015 2007 - 2015  2006 - 2007  2004 - 2006  2004 1999 - 2003 2001 - 2004 1999 - 2004 1999 - 2004  1998 - 1999	<b>drugsafety.ch, Küsnacht, Zurich, Switzerland</b> Founder and CEO  <b>Institute of General Internal Medicine and Nephrology, Clinic Hirslanden, Zurich</b> Senior Consulting Physician  <b>Center for Internal Medicine (ZIM), Clinic Hirslanden, Aarau</b> Senior Consulting Physician  <b>Swiss Federal Institute of Technology Zurich (ETHZ)</b> <b>Department of Chemistry and Applied Biosciences, Pharmaceutical Sciences</b> Lecturer of Pharmacoepidemiology and Drug Safety  <b>Department of Clinical Pharmacology and Toxicology</b> <b>University Hospital Zurich, Zurich, Switzerland (Prof. G.A. Kullak-Ublick)</b> Head of Pharmacoepidemiology and Drug Safety Senior Physician (Oberarzt) Clinical Pharmacology and Toxicology  <b>The Degge Group Drug Safety &amp; Pharmacoepidemiology, Arlington, VA, USA (Prof. J.K. Jones)</b> Medical and Research Director  <b>Boston Collaborative Drug Surveillance Program, Boston University, Boston, MA, USA (Prof. H. Jick)</b> Research Fellow in Pharmacoepidemiology  <b>Department of Clinical Pharmacology, University of Berne, Berne, Switzerland (Prof. B.H. Lauterburg, Prof. J. Reichen)</b> Fellow (stv. Oberarzt) in Clinical Pharmacology Resident (Assistenzarzt) in Clinical Pharmacology Clinical Trials Investigator, Clinical Investigation Unit, University Hospital Berne Adverse drug reactions case assessor and reporter Swiss Regional Pharmacovigilance Center Berne Member of Prof. B.H. Lauterburg's research group, University of Berne  <b>Heart Center Bad Krozingen, Bad Krozingen, Germany (Prof. H. Roskamm)</b> Internship (Arzt im Praktikum) in cardiology and internal medicine

<b>Undergraduate education and training</b>	<p>1994 - 1997 1993 - 1994 1990 - 1993</p> <p>1990 - 1997</p>	<p><b>Medical School</b> Faculty of Medicine, Albert-Ludwigs University, Freiburg, Germany St.Mary's Hospital Medical School, Imperial College, London, UK Faculty of Medicine, Albert-Ludwigs University, Freiburg, Germany</p> <p><b>Practical training (elective periods) during Medical School</b> Pediatrics, University Hospital, Freiburg, Germany Surgery, General Hospital Samedan, Switzerland Internal medicine, Mount Sinai Hospital, New York, USA Internal medicine, University Hospital, Grenoble, France Surgery, Hadassah University Hospital, Jerusalem, Israel Radiology, Private practice, Freiburg, Germany Cardiology, General Hospital, Aix-en-Provence, France Orthopedic surgery, Hammersmith Hospital, London, UK</p>
<b>Doctoral students trained</b>	<p>2016 2012 2011 2011 2007 2002</p>	<p>David Niedrig (Dr. sc. nat, ETH Zurich) Daniela Fritz (Dr. med, University of Zurich) Thomas Frölich (Dr. med, University of Zurich) Markus Guzek (Dr. med, University of Zurich) Emmilia A. Dowlatshahi (Dr. med, University of Freiburg, Germany) Franziska Zenger (Dr. med, University of Berne)</p>
<b>Master students trained</b>	<p>2017 - 2018 2011 2011</p>	<p>Emiri Grimes (MSc Pharmaceutical Sciences, ETH Zurich), grade: 4.5/6 Patrick Haueis (MSc Pharmaceutical Sciences, ETH Zurich), grade: 6/6 Olesya I. Zorina (MSc Pharmaceutical Sciences, ETH Zurich), grade: 5.75/6</p>
<b>Academic research grants and awards, scholarships</b>	<p>2015  2014  2013  2012 - 2015  2012 - 2013  2010  2009  2009  2007</p>	<p>Research grant from Takeda Pharma AG for the project "Pharmacotherapy and Drug Safety in Swiss Psychiatric Hospitals: Setup of a Pharmacoepidemiological Database and Research Platform"</p> <p>Research grant from Takeda Pharma AG for the project "Pharmacoepidemiological Studies on Prescribing Patterns and Metabolic Profiles in Patients Using Atypical Antipsychotics in Switzerland"</p> <p>University Hospital Zurich Quality Board Award for the project „Improving Hospital Drug Safety Using Combined Retro- and Prospective Identification of Medication Errors with Computer-supported Highly Specific Alerts"</p> <p>Research grant from Swiss National Science Foundation (SNF) for the project „Improving Hospital Drug Safety - Targeted Electronic Alerts and Subsequent Interrupted Time Series Regression Analyses of Outcomes"</p> <p>Research grant from ID Suisse AG for the project „Improving acceptance and efficacy of clinical decision support systems"</p> <p>Research grant from Zurich Center for Integrative Human Physiology (ZIHP), Co-investigator on the project "Role and Regulation of FGF23 in Health and Chronic Kidney Disease"</p> <p>Research grants from Swiss Society for Drug Safety in Psychiatry (SGAMSP) and Hartmann Müller foundation for the project „Evaluation of drug interactions in medication data of psychiatric inpatients from the AMSP program through the comparative use of electronic prescription support software solutions".</p> <p>Research grant from Center for Clinical Research (ZKF), University Hospital Zurich for the project "Evaluation of medication safety in neurological inpatients using electronic drug prescription data and prescription support software"</p> <p>Research Encouragement Award of the Swiss Society of Gastroenterology, sponsored by Astra Zeneca AG</p>

	2004	Two-year International Fellowship in Clinical Pharmacology Merck Sharp & Dohme (MSD) foundation
	2004	One-year foreign research training grant (PBBEB--104453) from Swiss National Science Foundation (SNF), for the project "Pharmacoepidemiological studies in the General Practice Research Database (GPRD)" at Boston University, USA <i>(returned in favor of the MSD foundation fellowship scholarship)</i>
	1993	German Academic Exchange Service (DAAD), 1-year scholarship for Medical Studies at St. Mary's Hospital Medical School, Imperial College, London, UK
<b>Awards to young scientists under my supervision</b>	2015	David Niedrig, Award for the best oral presentation "Retrospective Mass-Analysis of Hospital Prescription Data for Medication Errors and Subsequent Development of Highly Specific Alert Algorithms with ID PHARMA CHECK®" at the Annual Meeting of the Swiss Society of Public Health Administration and Hospital Pharmacists (SGASA)
	2013	Regina Krattinger, SGIM Award for the scientific poster „Introduction and Outcome Analysis of Systematic Semi-Automated Alerts Regarding Metformin Dose-Adjustment in Patients with Renal Impairment in a Swiss University Hospital"
	2012	Patrick Haueis, Rudolf-Buchheim Award by DGPT for the publication „Evaluation of Drug Interactions in 84,607 Psychiatric Inpatients Using A Data Interface for Mass Analysis with Clinical Decision Support Software" in Clin Pharmacol Ther 2011
<b>Scientific societies memberships and appointments</b>	2009 - 2015	Centre for Integrative Human Physiology (ZIHP), University of Zurich (2009 junior membership, 2013 full membership)
	2004 - present	International Society of Pharmacoepidemiology (ISPE)
	2002 - present	International Society of Pharmacovigilance (ISoP), <b>Current Vice-President of the Swiss-Austrian ISoP chapter</b>
	2000 - present	Swiss Society of Pharmacology and Toxicology, Section of Clinical Pharmacology (SGKPT)
	2001 - present	Swiss Association for the Study of the Liver (SASL)
	1997 - present	German Society of Pharmacology and Toxicology, Section of Clinical Pharmacology (DGPT)
	2009 - present	Swiss Society for Drug Safety in Psychiatry (SGAMSP), Past Vice-President
	2012 - present	Swiss Society for Medical Informatics (SGMI)
<b>Certified postgraduate training courses</b>	2005 - 2006	Principles of Clinical Pharmacology A.J. Atkinson Jr., Clinical Center, National Institutes of Health, Bethesda, USA
	2005	Introduction to Epidemiology P. Sorlie, FAES Graduate School, National Institutes of Health, Bethesda, USA
	2005	Principles of Pharmacokinetic Data Analysis: Modeling and Simulation using SAAM II software A.J. Atkinson Jr. & D.M. Foster, Center for Information Technology, National Institutes of Health, Bethesda, USA
	2000	Advanced Methods in Pharmacokinetics / Pharmacodynamics M. Rowland, Manchester, UK, & L. Sheiner, San Francisco, USA
	1999	Emergency medicine (Notarzausbildung) 1-week course in Langenargen and practical training at German Red Cross (DRK) rescue base Bad Krozingen, affiliated with Herz-Zentrum Bad Krozingen

**Reviewing  
activities**

Regular peer-reviews for scientific journals including:

Amer J Gastroenterol  
Artificial Intelligence in Medicine  
BMC Family Practice  
Cell Biology and Toxicology  
Clin Infect Dis  
Curr Drug Metabolism  
Curr Med Chemistry  
Dig Liver Dis  
Drug Safety  
Eur J Clin Nutr  
Eur J Clin Pharmacol  
Exp Opinion on Metabolism and Toxicology  
Int J Epidemiol  
J Hepatol  
J Mol Medicine  
Liver International  
Med J Australia  
North American Journal of Medical Sciences  
**Pharmacoepidemiol Drug Saf**  
**(selected as best reviewer by the editors in 2013, 2014 and 2015)**  
Swiss Medical Weekly  
The Open Addiction Journal

## SCIENTIFIC PUBLICATIONS

### I. Peer-reviewed original articles

1. Meincke R, Pokladnikova J, Straznicka J, Meyboom RH, Niedrig D, **Russmann S**, Jahodar L  
Allergy-like immediate reactions with herbal medicines in children: a retrospective study using data from Vigibase®  
Pediatric Allergy and Immunology, doi: 10.1111/pai.12778, in press  
(Impact factor: 3.775)
2. Heinrich H, Neuenschwander A, **Russmann S**, Misselwitz B, Benden C, Schuurmans MM  
Prevalence of gastrointestinal dysmotility and complications detected by abdominal plain films after lung transplantation: a single-centre cohort study.  
BMJ Open Res 2016;3:e000162. doi:10.1136/bmjresp-2016-000162  
(Impact factor: n.a.)
3. Niedrig DF, Hoppe L, Mächler S, Russmann H, **Russmann S**.  
Benzodiazepine Use During Hospitalization: Automated Identification of Potential Medication Errors and Systematic Assessment of Preventable Adverse Events.  
PLoS One. 2016 Oct 6;11(10):e0163224  
(Impact factor: 3.54)
4. Niedrig DF, Bucklar G, Fetzer M, Mächler S, Gött C, **Russmann S**.  
Paracetamol overdosing in a tertiary care hospital: implementation and outcome analysis of a preventive alert programme.  
J Clin Pharm Ther. 2016 Oct;41(5):515-8.  
(Impact factor: 1.833)
5. Niedrig D, Krattinger R, Jödicke A, Gött C, Bucklar G, **Russmann S**.  
Development, implementation and outcome analysis of semi-automated alerts for metformin dose adjustment in hospitalized patients with renal impairment.  
Pharmacoepidemiol Drug Saf. 2016 Oct;25(10):1204-1209  
(Impact factor: 2.908)
6. Niedrig DF, Mächler S, Hoppe L, Corti N, Kovari H, **Russmann S**  
Drug Safety of Macrolide and Quinolone Antibiotics in a Tertiary Care Hospital: Administration of Interacting Comedication and QT-Prolongation  
European Journal of Clinical Pharmacology 2016, Jul; 72(7):859-67  
(Impact factor: 2.966)
7. Pokladnikova J, Meyboom RH, Meincke R, Niedrig D, **Russmann S**.  
Allergy-Like Immediate Reactions with Herbal Medicines: A Retrospective Study Using Data from Vigibase®.  
Drug Saf. 2016 May; 39(5):455-64  
(Impact factor: 2.824)
8. Niedrig DF, Gött C, Fischer A, Müller ST, Greil W, Bucklar G, **Russmann S**  
Second-generation Antipsychotics in a Tertiary Care Hospital - Prescribing Patterns, Metabolic Profiles and Drug Interactions  
International Clinical Psychopharmacology 2016 Jan;31(1):42-50  
(Impact factor: 3.098)
9. Kovari H, **Russmann S**, Ledergerber B, Müller D, Rotger M, Velli P, Cavassini M, Ambrosioni J, Bregenzer A, Stöckle M, Bernasconi E, Rauch A, Speck RF  
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study  
PLOS One 2015 Jul 28;10(7): e0133879  
(Impact factor: 3.534)

10. **Russmann S**, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA.  
Rivaroxaban postmarketing risk of liver injury.  
J Hepatol. 2014; 61:293-300  
(Impact factor: 9.858)
11. Zorina OI, Haueis P, Greil W, Grohmann R, Kullak-Ublick GA, **Russmann S**.  
Comparative Performance of Two Drug Interaction Screening Programs Analyzing a Cross-sectional Prescription Dataset of 84,625 Psychiatric Inpatients.  
Drug Saf. 2013 Apr;36(4):247-58  
(Impact factor: 3.634)
12. Bloch-Teitelbaum A, Lüde S, Rauber-Lüthy C, Kupferschmidt H, **Russmann S**, Kullak-Ublick GA, Ceschi A.  
Medication wrong route administration: a poisons centre-based study.  
Expert Opin Drug Saf. 2013 Mar;12(2):145-52  
(Impact factor: 3.015)
13. Rau M, Stickel F, **Russmann S**, Manser C, Becker P, Weisskopf M, Schmitt J, Dill MT, Dufour JF, Moradpour D, Semela D, Müllhaupt B, Geier A.  
Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection.  
J Hepatol. 2013 Apr;58(4):669-75  
(Impact factor: 9.858)
14. Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, **Russmann S**, Serra AL.  
Secreted Klotho and FGF23 in chronic kidney disease stage 1 to 5: A sequence suggested from a cross-sectional study.  
Nephrol Dial Transplant. 2013 Feb;28(2):352-9  
(Impact factor: 3.396)
15. Haeberle A, Greil W, **Russmann S**, Grohmann R  
Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP.  
BMC Psychiatry. 2012 Sep 21;12:153  
(Impact factor: 2.55)
16. Taegtmeier A, Curkovic I, Corti N, Rosen C, Egbring M, **Russmann S**, Gantenbein A, Weller M, Kullak-Ublick G.  
Drug-related problems and factors influencing acceptance of clinical pharmacologists` alerts in a large cohort of neurology inpatients.  
Swiss Med Wkly 2012, Jul 9;142:13615  
(Impact factor: 1.823)
17. Zorina OI, Haueis P, Semmler A, Marti I, Gonzenbach RR, Guzek M, Kullak-Ublick GA, Weller M, **Russmann S**.  
Comparative Evaluation of the Drug Interaction Screening Programs MediQ and ID PHARMA CHECK in Neurological Inpatients  
Pharmacoepidemiology and Drug Safety 2012, Aug;21(8):872-80  
(Impact factor: 2.342)
18. Fritz D, Ceschi A, Curkovic I, Huber M, Egbring M, Kullak-Ublick GA, **Russmann S**.  
Comparative Evaluation of Three Clinical Decision Support Systems: Prospective Screening for Medication Errors in 100 Medical Inpatients.  
Eur J Clin Pharmacol 2012, Aug;68(8):1209-19  
(Impact factor: 3.032)
19. Greil W, Häberle A, Haueis P, Grohmann R, **Russmann S**  
Pharmacotherapeutic Trends in 2,231 Psychiatric Inpatients with Bipolar Depression from the International AMSP Project between 1994 and 2009.  
J Affective Disorders 2012, Feb;136(3):534-42  
(Impact factor: 3.740)

20. Haueis P, **Russmann S**, Zorina O, Grohmann R, Kullak-Ublick GA, Jaquenoud Sirot E, Russmann H. Coprescription of Levodopa with Antipsychotics in a Population of 84,596 Psychiatric Inpatients from 1994 to 2008. *Pharmacopsychiatry* 2012, Jun; 45(4):127-32 (Impact factor: 2.203)
21. Frölich T, Zorina O, Fontana AO, Kullak-Ublick GA, Vollenweider A, **Russmann S**. Evaluation of Medication Safety in the Discharge Medication of 509 Surgical Inpatients Using Electronic Prescription Support Software and an Extended Operational Interaction Classification. *Eur J Clin Pharmacol* 2011, Dec;67(12):1273-82 (Impact factor: 3.032)
22. Haueis P, Greil W, Huber M, Grohmann R, Kullak-Ublick GA, **Russmann S**. Evaluation of Drug Interactions in 84,607 Psychiatric Inpatients Using A Data Interface for Mass Analysis with Clinical Decision Support Software. *Clinical Pharmacology & Therapeutics* 2011, Oct;90(4):588-96. (Impact factor: 6.378)
23. Guzek M, Zorina O, Semmler A, Gonzenbach R, Huber M, Kullak-Ublick GA, Weller M, **Russmann S**. Evaluation of Drug Interactions and Dosing in 484 Neurological Inpatients Using Clinical Decision Support Software and an Extended Operational Interaction Classification System (ZHIAS) *Pharmacoepidemiology and Drug Safety* 2011, Sep;20(9):930-8 (Impact factor: 2.342)
24. Bihl F, **Russmann S**, Gurtner V, Di Giammarino L, Pizzi-Bosman L, Michel M, Cerny A, Hadengue A, Majno P, Giostra E, Castelli D, Mentha G. Hyperimmune Anti-HBs Plasma as Alternative to Commercial Immunoglobulins for Prevention of HBV Recurrence After Liver Transplantation. *BMC Gastroenterol* 2010, Jul 4; 10:71 (Impact factor: 2.47)
25. Egbring M, Kullak-Ublick GA, **Russmann S**. Phynx - An Open Source Software Solution Supporting Data Management and Web-based Patient-Level Data Review for Drug Safety Studies in the General Practice Research Database and Other Health Care Databases. *Pharmacoepidemiology and Drug Safety* 2010 Jan; 19(1):38-44. (Impact factor: 2.342)
26. Motsko SP, **Russmann S**, Ming EE, Singh VP, Vendiola R, Jones JK. Effectiveness of Rosuvastatin Compared to Other Statins for the Prevention of Cardiovascular Events - A Cohort Study in 395'039 Patients from Clinical Practice. *Pharmacoepidemiology and Drug Safety* 2009 Dec; 18(12):1214-22. (Impact factor: 2.342)
27. **Russmann S**, Lamerato L, Motsko SP, Pezzullo J, Faber MD, Jones JK. Risk of Further Decline in Renal Function After Use of Oral Sodium Phosphate or Polyethylene Glycol in Patients With a Preexisting Glomerular Filtration Rate Below 60 ml/min. *American Journal of Gastroenterology* 2008 Nov, 103(11):2707-16. (Impact factor: 6.882)
28. Serra AL, Braun SC, Starke A, Savoca R, Hersberger M, **Russmann S**, Corti N, Wüthrich RP. Pharmacokinetics and Pharmacodynamics of Cinacalcet in Patients with Hyperparathyroidism after Renal Transplantation. *American Journal of Transplantation* 2008 Apr; 8(4):803-10. (Impact factor: 6.051)

29. **Russmann S**, Lamerato L, Marfatia A, Motsko SP, Pezzullo J, Olds G, Jones JK.  
Risk of Impaired Renal Function After Colonoscopy: A Cohort Study in Patients Receiving Either Oral Sodium Phosphate or Polyethylene Glycol.  
American Journal of Gastroenterology 2007 Dec;102(12):2655-63.  
(Impact factor: 6.882)
30. **Russmann S**, Dowlatshahi EA, Printzen G, Habicht S, Reichen J, Zimmermann H.  
Prevalence and Associated Factors of Viral Hepatitis and Transferrin Elevations in 5036 Patients Admitted to the Emergency Room of a Swiss University Hospital: Cross-sectional Study.  
BMC Gastroenterol 2007 Feb 5;7(1):5  
(Impact factor: 2.47)
31. Jick H, Kaye JA, **Russmann S**, Jick S.  
NSAIDs and acute myocardial infarction in patients with no major risk factors.  
Pharmacotherapy 2006; 26(10):1379-87.  
(Impact factor: 2.631)
32. Jick SS, Kaye JA, **Russmann S**, Jick H.  
Risk of Nonfatal Venous Thromboembolism Comparing Oral Contraceptives Containing Norgestimate or Desogestrel with Oral Contraceptives Containing Levonorgestrel.  
Contraception 2006; 73(6):566-570.  
(Impact factor: 2.511)
33. Jick SS, Kaye JA, **Russmann S**, Jick H.  
Risk of non-fatal venous thromboembolism comparing ORTHO EVRA™ with oral contraceptives containing norgestimate and 35 µg of ethinyl estradiol.  
Contraception 2006; 73(3);223-228.  
(Impact factor: 2.511)
34. Grattagliano I, **Russmann S**, Palmieri VO, Portincasa P, Palasciano G, Lauterburg BH.  
Glutathione peroxidase, thioredoxin and membrane protein changes in erythrocytes predict ribavirin-induced anemia.  
Clinical Pharmacology & Therapeutics 2005;78:422-32.  
(Impact factor: 6.378)  
**S. Russmann is shared first author**
35. **Russmann S**, Kaye JA, Jick SS, Jick H.  
Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database.  
Br J Clin Pharmacol 2005;60(1):76-82.  
(Impact factor: 3.063)
36. Zenger F, **Russmann S**, Junker E, Wüthrich C, Bui MH, Lauterburg BH.  
Decreased glutathione in patients with anorexia nervosa. Risk factor for toxic liver injury?  
Eur J Clin Nutr 2004;58(2):238-43.  
(Impact factor: 2.561)
37. Naef M, **Russmann S**, Petersen-Felix S, Brenneisen R.  
Development and pharmacokinetic characterization of pulmonary and intravenous delta-9-tetrahydrocannabinol (THC) in humans.  
J Pharm Sci 2004;93(5):1176-84.  
(Impact factor: 3.031)
38. Grattagliano I, **Russmann S**, Palmieri VO, Jüni P, Bihl F, Portincasa P, Palasciano G, Lauterburg BH.  
Low membrane protein sulfhydryls but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C.  
Hepatology 2004;39(5):1248-55.  
(Impact factor: 11.665)  
**S. Russmann is shared first author and corresponding author**



39. Brenneisen R, Elshohly MA, Murphy TP, Passarelli J, **Russmann S**, Salamone SJ, Watson DE. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. *J Anal Toxicol* 2004;28(8):625-30. (Impact factor: 1.545)
40. Baumann R, Yousefi S, Simon D, **Russmann S**, Mueller C, Simon HU. Functional expression of CD134 by neutrophils. *Eur J Immunol* 2004;34(8):2268-75. (Impact factor: 4.942)
41. **Russmann S**, Junker E, Lauterburg BH. Remethylation and transsulfuration of methionine in cirrhosis: studies with L-[<sup>2</sup>H<sub>3</sub>-methyl-1-<sup>13</sup>C]methionine. *Hepatology* 2002;36(5):1190-6. (Impact factor: 11.665)
42. **Russmann S**, Dilger K, Trenk D, Nagyivanyi P, Jähnchen E. Effect of lysine clonixinate on the pharmacokinetics and anticoagulant activity of phenprocoumon. *Arzneimittel-Forschung - Drug Research* 2001;51(11):891-5. (Impact factor: 0.632)
43. **Russmann S**, Gohlke-Bärwolf C, Jähnchen E, Trenk D, Roskamm H. Age-dependent differences in the anticoagulant effect of phenprocoumon in patients after heart valve surgery. *Eur J Clin Pharmacol* 1997;52(1):31-5. (Impact factor: 3.032)

## II. Peer-reviewed review articles

1. Grattagliano I, **Russmann S**, Diogo C, Bonfrate L, Oliveira PJ, Wang DQ, Portincasa P. Mitochondria in Chronic Liver Disease. *Curr Drug Targets* 2011;12(6):879-893. (Impact factor: 3.061)
2. **Russmann S**, Jetter A, Kullak-Ublick GA. Pharmacogenetics of Drug-induced Liver Disease. *Hepatology* 2010, 52(2):748-61. (Impact factor: 11.665)
3. **Russmann S**, Curkovic I, Huber M. Adverse Reactions and Risks Associated with Non Compliance. *Ther Umsch* 2010 Jun;67(6):303-7. (Impact factor: n.a.)
4. **Russmann S**, Kullak-Ublick GA, Grattagliano I. Current Concepts of Mechanisms in Drug-induced Hepatotoxicity. *Curr Med Chem* 2009; 16:3041-3053. (Impact factor: 4.63)
5. **Russmann S**, Szeless T, Bock A, Kullak-Ublick GA. Natriumphosphat enthaltende Darmreinigungsmittel - Gefahr für die Niere? *Swiss Medical Forum* 2009; 9(18):336-9. (Impact factor: n.a.)
6. **Russmann S**, Portincasa P, Palmieri VO, Palasciano G, Grattagliano I. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. *Curr Med Chem* 2006; 13 (27):3351-7. (Impact factor: 4.63)

7. **Russmann S**, Lauterburg BH.  
Life-threatening adverse effects of pharmacologic antihyperuricemic therapy.  
Ther Umsch 2004;61(9):575-7.  
(Impact factor: n.a.)
8. **Russmann S**, Lauterburg BH.  
Drug-induced liver diseases.  
Swiss Medical Forum 2002(44):1044-50.  
(Impact factor: n.a.)

### III. Monographies

1. **Russmann S**  
Methodological Options for the Evaluation of Drug Safety: From Spontaneous Reports to Pharmacoepidemiology  
Habilitationsschrift, University of Zurich, Faculty of Medicine, 30 May 2007

### IV. Book chapters

1. **Russmann S**, Kullak-Ublick GA.  
Arzneimittelsicherheit  
In: Kullak-Ublick GA, Siepmann T, Kirch W, editors. *Arzneimitteltherapie*. Thieme, 2012: Chapter 1.3
2. Sift Carter R, Stoller R, **Russmann S**.  
Unerwünschte Arzneimittelwirkungen  
In: Kullak-Ublick GA, Siepmann T, Kirch W, editors. *Arzneimitteltherapie*. Thieme, 2012: Chapter 1.3.1
3. **Russmann S**.  
Arzneimittelsicherheit in klinischen Studien  
In: Kullak-Ublick GA, Siepmann T, Kirch W, editors. *Arzneimitteltherapie*. Thieme, 2012: Chapter 1.3.2
4. Sift Carter R, **Russmann S**, Stoller R.  
Pharmakovigilanz  
In: Kullak-Ublick GA, Siepmann T, Kirch W, editors. *Arzneimitteltherapie*. Thieme, 2012: Chapter 1.3.3
5. **Russmann S**  
Pharmakoepidemiologie  
In: Kullak-Ublick GA, Siepmann T, Kirch W, editors. *Arzneimitteltherapie*. Thieme, 2012: Chapter 1.3.4
6. Egbring M, **Russmann S**, Kullak-Ublick GA.  
Clinical Decision Support Systems  
In: Kullak-Ublick GA, Siepmann T, Kirch W, editors. *Arzneimitteltherapie*. Thieme, 2012: Chapter 1.3.5
7. **Russmann S**, Reichen J.  
Drug prescription in liver disease.  
In: Weinstein WM, Hawkey CJ, Bosch J, editors. *Clinical Gastroenterology and Hepatology*. 1st ed: Elsevier Science, 2005: Chapter 137, 1015-1019.
8. **Russmann S**, Reichen J.  
Drug-induced and toxic liver disease.  
In: Weinstein WM, Hawkey CJ, Bosch J, editors. *Clinical Gastroenterology and Hepatology*. 1st ed: Elsevier Science, 2005: Chapter 92, 677-686.
9. **Russmann S**, Lauterburg BH.  
Environmental toxicology of the liver.  
In: Wichmann, Schlipkötter, Fülgraff, editors. *Manual of Environmental Medicine*, V5, 1-26, EcoMed, 2003.

## V. Peer-reviewed case reports and letters

1. Aellig N, Krüger B, Schwartz T, Kullak-Ublick GA, Schmid-Grendelmeier P, **Russmann S**.  
Chlorhexidin-Allergie: Anaphylaktische Reaktionen auf das Desinfiziens können lebensbedrohend sein.  
Swiss Medical Forum 2014, in press.  
(Impact factor: n.a.)
2. Weiss T, Müller D, Marti I, Happold C, **Russmann S**.  
Gamma-hydroxybutyrate (GHB) and topiramate - clinically relevant drug interaction suggested by a case of coma and increased plasma GHB concentration.  
Eur J Clin Pharmacol. 2013 May;69(5):1193-4.  
(Impact factor: 3.032)
3. Gonzenbach RR, Taegtmeyer AB, Luft A, **Russmann S**.  
Interaction between Fluoxetine and Clopidogrel after Acute Ischemic Stroke.  
Lancet Neurology 2011 Jun; 10(6): 499-500  
(Impact factor: 21.659)
4. Prinz Vavricka BM, Baumbegrer P, **Russmann S**, Kullak-Ublick GA.  
Diagnosis of Melanoma under Concomitant Natalizumab Therapy.  
Mult Scler 2011 Feb; 17(2):255-6  
(Impact factor: 3.28)
5. **Russmann S**.  
Case reports of suspected adverse drug reactions: case reports generate signals efficiently.  
Brit Med J 2006; Feb 25; 332(7539):488  
(Impact factor: 13.471)
6. **Russmann S**, Lauterburg BH, Barguil Y, Choblet E, Cabalion P, Rentsch K, Wenk M.  
Traditional aqueous kava extracts inhibit cytochrome P4501A2 in humans: Protective effect against environmental carcinogens?  
Clinical Pharmacology & Therapeutics 2005;77(5):453-454.  
(Impact factor: 6.378)  
*Original research formally published as a letter*
7. **Russmann S**, Iselin HU, Meier D, Zimmermann A, Simon HU, Caduff P, Reichen J.  
Acute hepatitis associated with montelukast.  
J Hepatol 2003;38(5):694-5.  
(Impact factor: 9.264)
8. Bertoli R, Girardin F, **Russmann S**, Lauterburg BH.  
Raynaud's phenomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod.  
Eur J Clin Pharmacol 2003;58(10):717.  
(Impact factor: 3.032)  
*S. Russmann is corresponding author*
9. **Russmann S**, Barguil Y, Cabalion P, Kritsanida M, Duhet D, Lauterburg BH.  
Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia.  
Eur J Gastroenterol Hepatol 2003;15(9):1033-6.  
(Impact factor: 1.598)  
*Original research formally published as a case report*
10. **Russmann S**, Winkler A, Lovblad KO, Stanga Z, Bassetti C.  
Lethal ischemic stroke after cisplatin-based chemotherapy for testicular carcinoma and cannabis inhalation.  
Eur Neurol 2002;48(3):178-80.  
(Impact factor: 1.49)

11. **Russmann S**, Zimmermann A, Krähenbühl S, Kern B, Reichen J.  
Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis.  
Eur J Gastroenterol Hepatol 2001;13(3):287-90.  
(Impact factor: 1.598)
12. **Russmann S**, Lauterburg BH, Helbling A.  
Kava hepatotoxicity.  
Ann Intern Med 2001;135(1):68-9.  
(Impact factor: 16.7)

## VI. Other publications

1. **Russmann S**, Kullak-Ublick GA.  
Assessment and reporting of drug-induced liver injury  
Vigilance-News Swissmedic, No. 10, 2012.
2. **Russmann S**  
Praxis und Perspektiven der Arzneimittelsicherheit  
Ärztewoche - Special Issue for the 43<sup>rd</sup> Annual Meeting of the Austrian Society of Internal Medicine. 20. September 2012.
3. **Russmann S**  
Risiko von Arzneimittelinteraktionen - Therapie optimieren, Interaktionen vermeiden  
Medical Tribune Special, Fortbildung Kompakt, 10/2012: 25-26
4. **Russmann S**, Kullak-Ublick GA.  
Drug-induced Liver Disease  
Chapter for the iOS (iPhone/iPad) application and clinician guide "iLiver"  
Edited by the European Association for the Study of the Liver (EASL). Release date April 2012.
5. **Russmann S**, Lauterburg BH.  
Die Clinical Investigation Unit am Inselspital.  
Inselbote 2004; Nr.1 (Frühling):30-33.